Analysis of Global Gastrointestinal Drugs Market Industry 2023


Posted May 29, 2018 by kishor8796

Gastrointestinal Drugs Market report provides the latest market data along with industry future trends, which keeps tracking of users driving revenue growth rate of Gastrointestinal Drugs Market

 
Gastrointestinal Drugs Market report provides the latest market data along with industry future trends, which keeps tracking of users driving revenue growth rate of Gastrointestinal Drugs Market by drug category(acid neutralizers, antidiarrheal & laxatives, anti-inflammatory), route of administration(oral, parenteral, rectal) market status and outlook of global and major regions, from manufacturers, and end industries. As this report is expected to help key players among the Gastrointestinal Drugs Market it includes the five years Industry analysis and the 6 years annual forecast from 2017 to 2023. Some of the prominent participants in the Global Gastrointestinal Drugs Market are Allergan Plc, AstraZeneca, Bayer AG, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., Janssen Biotech Inc., Sanofi, Takeda Pharmaceutical, and Valeant Pharmaceuticals Inc.

Get free Sample Pages of this Premium Report:-

https://www.infiniumglobalresearch.com/reports/sample_request/768

The Technological Reforms in the Treatment Offers Superior Outputs and Expected to Contribute Significantly in the Forthcoming Years

Global gastrointestinal drugs market experienced progressive growth over the past few years.  As per the report published by world gastrointestinal organization in 2015, almost 35%-40% of world’s population is suffering from acute and chronic gastrointestinal complications. This includes gastrointestinal disease and disorder, due to change and dietary pattern, which is predominantly responsible for global growth of this market. Moreover, rising prevalence of gastrointestinal disease across the globe is equally drives global growth. Increasing investment in research and development activities in older to develop new drugs along with growing awareness pertaining to availability of these treatments have raised considerable demand for GI drugs. Apart from this, technological reforms in the treatment offers superior outputs and expected to contribute significantly in the forthcoming years. The exact cause of GI related disorders are still unknown, due to which cure for these disorders is not available. This may hamper global growth of gastrointestinal drugs market by inviting various complications.

Global gastrointestinal market will have numerous growth opportunities during the forecasted period on account of technological advancement, significant unmet need for novel, safe and effective treatments and increasing geriatric population that highly susceptible to the disorders.

Segments Covered:

The report segments the global gastrointestinal drugs market by drug category, by route of administration, by disease type, by end user and by region. The market size of each segment has been provided in terms of value (USD). Market segmentation based on type of drugs category includes acid neutralizers, antidiarrheal and laxatives, antiemetic, anti-inflammatory, and others. Wherein acid neutralizer’s further sub segmented into antacids, H2 antagonists, and proton pump inhibitor. On the basis of route of administration global market has been segmented into oral, parenteral, and rectal. Moreover, market based on disease type includes gastro-esophageal reflux disorder (gerd), inflammatory bowel disease, and other, whereas, end user segment comprises hospital pharmacies, retail pharmacies and other.

North America is the Largest Market for Gastrointestinal Drugs Market, By Having Over 40% of Global Markets Shares In 2016

The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and Rest of the World. In this section the key trends and market size for each geography is provided over the period of 2017 – 2023.North America is the largest market for gastrointestinal drugs market, by having over 40% of global markets shares in 2016. The region anticipated to continue its dominance throughout the forecasted period. Moreover, U.S. and Mexico collectively drives the North American gastrointestinal market by contributing in the majority regional growth. Rising geriatric population base in the North America is the key driving factor in this region along with consumer friendly reimbursement policies for the treatment of chronic disease. Europe is the second largest market followed by Asia Pacific is at third place, both of these region almost acquired almost same market shares. Asia Pacific expected to emerge as most lucrative market over the forthcoming years. Improved medical and healthcare infrastructure, rise in public and private investment in life science research, technological advancements in the treatment of GI diseases in emerging economies have made this region favorable and to grow at highest CAGR.

Major Key Player Mentioned in this Report:

The companies covered in the report include Abbott Laboratories, Allergan Plc, AstraZeneca, Bayer AG, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., Janssen Biotech Inc., Sanofi, Takeda Pharmaceutical, and Valeant Pharmaceuticals Inc.

Table of Contents:

1. Preface

1.1 Report Description

1.2 Research Methods

1.3 Research Approaches

2. Executive Summary

3. Global Gastrointestinal Drugs Market Overview

3.1 Introduction

3.2 Market Dynamics

3.2.1 Drivers

3.2.2 Restraints

3.2.3 Opportunities

3.2.4 Challenges

3.3 Porter’s Five Forces Analysis

3.4 IGR – Growth Matrix Analysis

3.5 Competitive Landscape in the Gastrointestinal Drugs Market

4. Global Gastrointestinal Drugs Market: IGR Snapshots

4.1 Global Gastrointestinal Drugs Market key Trends

4.2 Global Gastrointestinal Drugs Market by Drug Category

4.3 Global Gastrointestinal Drugs Market by Route of Administration

4.4 Global Gastrointestinal Drugs Market by Disease Type

4.5 Global Gastrointestinal Drugs Market by Region

5. Global Gastrointestinal Drugs by Drug Category (USD Billion) 2017 – 2023

5.1 Acid Neutralizers

5.1.1 Antacids

5.1.2 H2 antagonists

5.1.3 Proton pump inhibitors

5.1.4 Helicobacter pylori eradication

5.2 Laxatives and Anti-diarrheal

5.3 Antiemetic and Antinauseants

5.4 Anti-Inflammatory

5.5 Biologics

5.6 Others

6. Global Gastrointestinal Drugs Market Analysis, by Route of Administration (USD Billion) 2017 – 2023

6.1 Oral

6.2 Parenteral

6.3 Rectal

7. Global Gastrointestinal Drugs Market Analysis, by Disease Type (USD Billion) 2017 – 2023

7.1 GERD (Gastroesophageal Reflux Disorder) `

7.2 Irritable Bowel Syndrome

7.3 Others

8. Global Gastrointestinal Drugs Market Analysis, by End User (USD Billion) 2017 – 2023

8.1 Hospital Pharmacies

8.2 Retail Pharmacies

8.3 Others

9. Global Gastrointestinal Drugs Market Analysis, by Region (USD Billion) 2017 – 2023

9.1 North America

9.1.1 North America Gastrointestinal Drugs Market by Drug Category (USD Billion)

9.1.2 North America Gastrointestinal Drugs Market by Route of Administration (USD Billion)

9.1.3 North America Gastrointestinal Drugs Market by Disease Type (USD Billion)

9.1.4 North America Gastrointestinal Drugs Market by End User (USD Billion)

9.2 Europe

9.2.1 Europe Gastrointestinal Drugs Market by Drug Category (USD Billion)

9.2.2 Europe Gastrointestinal Drugs Market by Route of Administration (USD Billion)

9.2.3 Europe Gastrointestinal Drugs Market by Disease Type (USD Billion)

9.2.4 Europe Gastrointestinal Drugs Market by End User (USD Billion)

9.3 Asia Pacific

9.3.1 APAC Gastrointestinal Drugs Market by Drug Category (USD Billion)

9.3.2 APAC Gastrointestinal Drugs Market by Route of Administration (USD Billion)

9.3.3 APAC Gastrointestinal Drugs Market by Disease Type (USD Billion)

9.3.4 APAC Gastrointestinal Drugs Market by End User (USD Billion)

9.4 RoW

9.4.1 ROW Gastrointestinal Drugs Market by Drug Category (USD Billion)

9.4.2 ROW Gastrointestinal Drugs Market by Route of Administration (USD Billion)

9.4.3 ROW Gastrointestinal Drugs Market by Disease Type (USD Billion)

9.4.4 ROW Gastrointestinal Drugs Market by End User (USD Billion)

10. Company Profiles

10.1 Abbott Laboratories

10.2 Allergan Plc

10.3 AstraZeneca

10.4 Bayer AG

10.5 Boehringer Ingelheim GmbH

10.6 GlaxoSmithKline Plc.

10.7 Janssen Biotech Inc.

10.8 Sanofi

10.9 Takeda Pharmaceutical

10.10 Valeant Pharmaceuticals Inc.

Browse Detailed TOC, Description and Companies Mentioned in Report @

https://www.infiniumglobalresearch.com/healthcare_medical_devices/global_gastrointestinal_drugs_market
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Infinium Global Research.Com
Phone 09923950043
Business Address Pune
Country India
Categories Business
Tags gastrointestinal drugs market analysis , gastrointestinal drugs market growth analysis , gastrointestinal drugs market product segment , gastrointestinal drugs market share , gastrointestinal drugs market size , gastrointestinal drugs market trends , gastrointestinal drugs market volume 2023 , research report gastrointestinal drugs market
Last Updated May 29, 2018